Is KPV legal in the US?

On no list at all — a weaker position than it sounds

“Is KPV legal” usually gets answered with the committee vote. The vote is not the status; the list is. A licensed 503A pharmacy may compound with a bulk substance that is not an approved drug in only three situations: the substance complies with a USP or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on the FDA’s 503A bulks list. KPV is in none of those positions, which is why no pharmacy in the United States can lawfully prepare it to a prescription today.

The middle door deserves a note, because it is closer than it looks. The FDA-approved melanocortin drug afamelanotide has the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ — it ends in the three residues sold as KPV. A component of an approved drug means an ingredient of the approved product, and the ingredient there is the whole tridecapeptide; a subsequence of an active ingredient is not itself a component. The FDA’s own conduct reads the same way: it kept KPV in the nomination process and put it before the advisory committee, which would be unnecessary if that door were open. We flag the point because no competing page raises it, not because the answer is in doubt.

Its interim standing is gone too, and the way it went is routinely misread. Until April 2026 KPV sat in Category 2 — substances for which the FDA had identified significant safety risks and would not extend enforcement discretion. On 15 April 2026 it left that category alongside eleven other peptides, and the reason was procedural: the parties that had nominated them withdrew the nominations. The FDA made no finding, resolved nothing and cleared nothing. KPV moved from “reviewed and flagged” to “not under consideration” — and Category 1, the only interim category that confers enforcement discretion, is not where it landed. What the three FDA categories mean, and what April 2026 actually did →

The vote covered more ground for KPV than for anything else on the agenda

Seven peptides went before the Pharmacy Compounding Advisory Committee on 23–24 July 2026, and each was judged against a named use rather than in general. BPC-157 was put to the committee for ulcerative colitis. TB-500 for wound healing. Epitalon for insomnia. KPV was put for wound healing and inflammatory conditions — one disease process and one open-ended category. It was recommended 8–6 with one abstention.

Two consequences follow, and both are usually missed. The committee voted separately on the free base and the acetate form, because the FDA treats peptide salt forms as chemically distinct substances — so “KPV” is two entries in the agency’s machinery, not one, and a rule could reach one and not the other. And a bulks listing, unlike an approval, carries no indication once it exists: the indication is what justifies putting a substance on the list, but it does not follow the substance onto the prescription pad. For a substance listed against “inflammatory conditions”, that gap is as wide as it gets.

Route is the variable to watch, and the FDA used it this year

Nothing has been proposed for KPV. But the FDA has shown, on this same docket and within the last six months, that it will write the route of administration into a bulk-substance entry rather than list a peptide whole.

The entry for the copper peptide GHK-Cu reads “GHK-Cu (except for injectable routes of administration)”, and sits in Category 1. It was removed on 22 April 2026 when the nominations were withdrawn; on 5 May 2026 one nominator clarified that it had meant to withdraw only the injectable route, and the carved-out entry is being restored. Non-injectable GHK-Cu is inside the interim policy; injectable GHK-Cu is on no list. One substance, two statuses, split by route.

KPV is the peptide where that tool would bite hardest. Its published research is oral and topical — nanoparticle delivery to inflamed gut tissue, topical application to eye and skin — while what circulates on the gray market is largely injectable, and immunogenicity from peptide aggregation in injectables was among the four objections FDA review staff raised in July. This is a precedent, not a prediction. It is the specific thing worth reading first if a proposed rule ever appears.

Where the enforcement risk actually sits

No public state action has named KPV. The two documented cases — Connecticut against a distributor in 2025, Alabama against an infusion clinic later that year — both concerned research-grade semaglutide and tirzepatide, GLP-1 drugs with approved counterparts, not the peptides under 503A review. The measure that does reach KPV is the Alabama Board of Medical Examiners’ official notice of May 2026: it names no individual peptide and therefore covers all of them, directing licensees not to advise, recommend, supply, prescribe, administer, compound or dispense non-FDA-approved research-grade peptides, and stating that a signed patient consent form does not reduce the provider’s liability. How the federal and state layers fit together →

KPV reaches people differently from an injectable, and that moves who is exposed. It is sold in oral and topical forms as well as vials, and it is the K in KLOW, one of the multi-peptide mixes sold under a brand name — what KPV is, and what it is not separates the substance from the things it is sold alongside. A blend has no regulatory standing of its own: compounding law works substance by substance, and the July votes covered single substances against single indications. Nothing about the vote reached a blend. This section describes the regulatory framework; it is not legal advice.

Sport: not named, not permitted

KPV is not named as an example anywhere on WADA’s 2026 Prohibited List. TB-500 is, under S2.3; BPC-157 is, under S0. Being unnamed is not being allowed — S0 reaches substances with no approval from any government health authority for human therapeutic use whether or not the list spells them out, and a violation does not require a positive test. Why the anti-doping regime is separate and stricter →

Primary sources: FDA 503A interim categories and bulk substances lists (Category 1 and Category 2, as published 14 May 2026) · FDA removal of twelve peptides from Category 2, 15 April 2026 (nominations withdrawn) · FDA list entry “GHK-Cu (except for injectable routes of administration)”, removal 22 April 2026 and nominator clarification 5 May 2026 · FDA Advisory Committee Calendar and Federal Register docket FDA-2025-N-6895 (PCAC, 23–24 July 2026) · section 503A of the FD&C Act · Controlled Substances Act schedules · Alabama Board of Medical Examiners, official notice on the prescribing of non-FDA-approved (research-grade) peptides (May 2026) · WADA 2026 Prohibited List.